130.35
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BIIB Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$127.85
Aprire:
$129.44
Volume 24 ore:
279.95K
Relative Volume:
0.19
Capitalizzazione di mercato:
$19.10B
Reddito:
$9.82B
Utile/perdita netta:
$1.48B
Rapporto P/E:
12.87
EPS:
10.13
Flusso di cassa netto:
$2.30B
1 W Prestazione:
+1.50%
1M Prestazione:
+4.51%
6M Prestazione:
-9.24%
1 anno Prestazione:
-41.87%
Biogen Inc Stock (BIIB) Company Profile
Nome
Biogen Inc
Settore
Industria
Telefono
(781) 464-2000
Indirizzo
225 BINNEY STREET, CAMBRIDGE, MA
Confronta BIIB con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
BIIB
Biogen Inc
|
130.38 | 18.68B | 9.82B | 1.48B | 2.30B | 10.13 |
![]()
LLY
Lilly Eli Co
|
787.47 | 692.83B | 49.00B | 11.11B | -1.27B | 12.29 |
![]()
JNJ
Johnson Johnson
|
167.15 | 373.35B | 90.63B | 22.66B | 18.57B | 9.35 |
![]()
ABBV
Abbvie Inc
|
188.20 | 329.24B | 57.37B | 4.20B | 15.39B | 2.35 |
![]()
NVS
Novartis Ag Adr
|
116.91 | 231.66B | 55.19B | 13.65B | 16.81B | 6.86 |
![]()
NVO
Novo Nordisk Adr
|
69.55 | 298.68B | 43.59B | 15.04B | 10.74B | 3.3766 |
Biogen Inc Stock (BIIB) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2025-07-21 | Ripresa | Truist | Hold |
2025-04-28 | Downgrade | HSBC Securities | Buy → Hold |
2025-04-04 | Downgrade | Argus | Buy → Hold |
2025-02-11 | Iniziato | Bernstein | Mkt Perform |
2025-01-02 | Downgrade | Piper Sandler | Overweight → Neutral |
2024-12-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
2024-12-16 | Downgrade | Stifel | Buy → Hold |
2024-12-10 | Ripresa | BofA Securities | Neutral |
2024-12-09 | Downgrade | Jefferies | Buy → Hold |
2024-11-18 | Downgrade | Needham | Buy → Hold |
2024-11-15 | Iniziato | Wolfe Research | Peer Perform |
2024-11-14 | Iniziato | Citigroup | Neutral |
2024-10-31 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
2024-10-10 | Ripresa | Raymond James | Mkt Perform |
2024-02-14 | Reiterato | Needham | Buy |
2024-02-14 | Downgrade | Wells Fargo | Overweight → Equal Weight |
2024-01-24 | Downgrade | UBS | Buy → Neutral |
2023-12-20 | Ripresa | Cantor Fitzgerald | Overweight |
2023-12-07 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
2023-09-06 | Iniziato | HSBC Securities | Buy |
2023-07-27 | Iniziato | Scotiabank | Sector Outperform |
2023-07-24 | Reiterato | UBS | Buy |
2023-05-01 | Aggiornamento | Guggenheim | Neutral → Buy |
2023-04-17 | Aggiornamento | Piper Sandler | Neutral → Overweight |
2022-10-26 | Aggiornamento | Goldman | Neutral → Buy |
2022-10-13 | Aggiornamento | Stifel | Hold → Buy |
2022-10-07 | Aggiornamento | Argus | Hold → Buy |
2022-09-28 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
2022-09-28 | Aggiornamento | Mizuho | Neutral → Buy |
2022-09-28 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
2022-04-18 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
2022-03-08 | Downgrade | Stifel | Buy → Hold |
2022-03-03 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
2022-02-04 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
2022-02-04 | Reiterato | Barclays | Equal Weight |
2022-02-04 | Reiterato | BofA Securities | Neutral |
2022-02-04 | Reiterato | Cowen | Outperform |
2022-02-04 | Reiterato | Morgan Stanley | Overweight |
2022-02-04 | Reiterato | Needham | Buy |
2022-02-04 | Reiterato | Oppenheimer | Outperform |
2022-02-04 | Reiterato | RBC Capital Mkts | Sector Perform |
2022-02-04 | Reiterato | Robert W. Baird | Neutral |
2022-02-04 | Reiterato | Wedbush | Neutral |
2022-02-04 | Reiterato | Wells Fargo | Equal Weight |
2022-02-04 | Reiterato | Wolfe Research | Peer Perform |
2022-01-13 | Downgrade | Guggenheim | Buy → Neutral |
2022-01-12 | Downgrade | Piper Sandler | Overweight → Neutral |
2021-12-10 | Ripresa | Raymond James | Mkt Perform |
2021-12-09 | Ripresa | Wells Fargo | Equal Weight |
2021-12-06 | Iniziato | Goldman | Neutral |
2021-11-19 | Iniziato | BMO Capital Markets | Outperform |
2021-09-23 | Iniziato | Needham | Buy |
2021-06-18 | Aggiornamento | Piper Sandler | Neutral → Overweight |
2021-06-14 | Reiterato | Truist | Buy |
2021-06-11 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
2021-06-10 | Aggiornamento | UBS | Neutral → Buy |
2021-06-08 | Aggiornamento | Atlantic Equities | Underweight → Neutral |
2021-06-08 | Reiterato | Barclays | Equal Weight |
2021-06-08 | Aggiornamento | Citigroup | Sell → Neutral |
2021-06-08 | Reiterato | H.C. Wainwright | Buy |
2021-06-08 | Reiterato | Jefferies | Buy |
2021-06-08 | Reiterato | Morgan Stanley | Overweight |
2021-06-08 | Reiterato | RBC Capital Mkts | Sector Perform |
2021-06-08 | Aggiornamento | Robert W. Baird | Underperform → Neutral |
2021-06-08 | Reiterato | Stifel | Buy |
2021-06-08 | Aggiornamento | William Blair | Mkt Perform → Outperform |
2021-06-07 | Aggiornamento | BofA Securities | Underperform → Neutral |
2021-06-07 | Aggiornamento | Cowen | Market Perform → Outperform |
2021-06-07 | Aggiornamento | Raymond James | Underperform → Mkt Perform |
2021-02-05 | Downgrade | DZ Bank | Buy → Hold |
2021-01-29 | Aggiornamento | Stifel | Hold → Buy |
2020-11-10 | Aggiornamento | DZ Bank | Hold → Buy |
2020-11-09 | Downgrade | Atlantic Equities | Neutral → Underweight |
2020-11-09 | Downgrade | BofA Securities | Neutral → Underperform |
2020-11-09 | Downgrade | Cowen | Outperform → Market Perform |
2020-11-09 | Reiterato | H.C. Wainwright | Buy |
2020-11-04 | Aggiornamento | BofA Securities | Underperform → Neutral |
2020-11-04 | Aggiornamento | Jefferies | Hold → Buy |
2020-11-04 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
2020-10-28 | Iniziato | UBS | Neutral |
2020-07-27 | Aggiornamento | Morgan Stanley | Underweight → Overweight |
2020-06-22 | Downgrade | Barclays | Overweight → Equal Weight |
2020-06-22 | Reiterato | RBC Capital Mkts | Sector Perform |
2020-06-09 | Downgrade | Bernstein | Outperform → Mkt Perform |
2020-04-23 | Downgrade | Citigroup | Neutral → Sell |
2020-04-23 | Downgrade | Raymond James | Mkt Perform → Underperform |
2020-03-31 | Iniziato | Wolfe Research | Peer Perform |
2020-02-27 | Iniziato | Barclays | Overweight |
2020-01-27 | Aggiornamento | Canaccord Genuity | Hold → Buy |
2019-12-13 | Aggiornamento | Credit Suisse | Underperform → Neutral |
2019-12-02 | Downgrade | Robert W. Baird | Neutral → Underperform |
Mostra tutto
Biogen Inc Borsa (BIIB) Ultime notizie
KLP Kapitalforvaltning AS Has $21.36 Million Holdings in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen to invest $2 billion in RTP, open new factory in 2025 - WRAL.com
Envestnet Asset Management Inc. Increases Stock Holdings in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Will Major North Carolina Expansion Change Biogen's (BIIB) Narrative? - simplywall.st
Biogen Inc. Stock Analysis and ForecastExceptional ROI - Autocar Professional
Beacon Investment Advisory Services Inc. Sells 3,529 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
FDA Names Biotech Veteran George Tidmarsh To Lead Drug Evaluation Division - Benzinga
Biogen, one of the largest employers in RTP, plans $2B investment in the Triangle - Axios
How Will AbbVie's Neuroscience Franchise Perform in Q2 Earnings? - The Globe and Mail
Allianz Asset Management GmbH Increases Stake in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Los Angeles Capital Management LLC Takes $5.93 Million Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Spinal Muscular Atrophy Treatment Market Growth Accelerated - openPR.com
Is Biogen Inc. a good long term investmentExplosive wealth accumulation - jammulinksnews.com
What drives Biogen Inc. stock pricePowerful growth strategies - jammulinksnews.com
Biogen: Hold Rating Amid Stagnant Growth and Uncertain Prospects - TipRanks
Biogen to invest additional $2B in North Carolina’s Research Triangle Park - MSN
Biogen to invest further $2bn in North Carolina’s Research Triangle Park - Yahoo Finance
Iovance Biotherapeutics shares rise 2.41% premarket after Biogen's $2 billion investment in North Carolina manufacturing. - AInvest
Biogen Inc. (BIIB) Partners with Stoke Therapeutics to Tackle Dravet Syndrome - MSN
What analysts say about Biogen Inc. stockFree Predictions - jammulinksnews.com
Biogen investing $2B to expand operations in RTP - ABC11
Biogen's Alzheimer's Innovation Pipeline: Lecanemab and BIIB080 as Catalysts for Long-Term Growth - AInvest
Biogen & Partner Eisai Get EU Nod for Alzheimer's Drug Leqembi - yahoo.co
Biogen to Highlight Scientific Progress Across Alzheimer’s Disease at the Alzheimer’s Association International Conference 2025 - Biogen
Biogen Inc. - Via Ritzau
Biogen to invest $2 billion in RTP facility - CBS 17
Biogen Inc. Invests $2B In North Carolina Expansion - Business Facilities
Biogen Inc. Announces $2 Billion Expansion in North Carolina's Research Triangle Park Amid U.S. Manufacturing Push - Hoodline
Friedreich's Ataxia Market Is Expanding Due To Advancing - openPR.com
Biogen (BIIB) Stock Trades Down, Here Is Why - Yahoo Finance
Biogen Bets Big On $2 Billion Expansion To Boost US Drug ManufacturingBiogen (NASDAQ:BIIB) - Benzinga
Biogen invests $2B in U.S. manufacturing — but not in Massachusetts - The Business Journals
Biogen to invest $2 billion in Research Triangle Park facilities - CBS 17
Biogen’s Pediatric RRMS Study Completion: Market Implications and Insights - TipRanks
Biogen (NASDAQ:BIIB) Coverage Initiated by Analysts at Truist Financial - MarketBeat
Biogen Invests $20 Billion in North Carolina to Counter 200% Tariff Threat - AInvest
Biogen to invest further $2 billion in North Carolina facilities - The Pharma Letter
Biogen beefs up North Carolina manufacturing ahead of potential drug tariff storm - Reuters
Drugmaker Biogen to invest $2 billion more in North Carolina - 104.1 WIKY
Truist downgrades Biogen, citing growth challenges, limited pipeline upside - TradingView
Biogen Announces Additional Investment In North Carolina's RTP - Nasdaq
Biogen (BIIB) Increases Investment in North Carolina Manufacturi - GuruFocus
Biogen to invest $2 billion more in North Carolina By Reuters - Investing.com
Biogen Announces $2 Billion Manufacturing Investment in North Carolina's Research Triangle Park in Conjunction with its 30th Anniversary | BIIB Stock News - GuruFocus
Biogen to invest $2 billion in North Carolina manufacturing expansion By Investing.com - Investing.com India
Biogen Announces $2 Billion Investment to Expand Manufacturing in North Carolina's Research Triangle Park - Quiver Quantitative
Biogen to invest $2 billion more in North Carolina - Reuters
Biogen Announces $2 Billion Manufacturing Investment in North Carolina’s Research Triangle Park in Conjunction with its 30th Anniversary - The Manila Times
Biogen Commits $2B for Manufacturing Expansion in Research Triangle Park | BIIB Stock News - Stock Titan
Twin Capital Management Inc. Has $1.58 Million Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Central Nervous System (CNS) Biomarkers Market is expected - openPR.com
Biogen Inc Azioni (BIIB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):